A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

The epidermal growth factor receptor (EGFR) inhibitors such as erlotinib and gefitinib are widely used for treatment of non-small cell lung cancer (NSCLC), but they have shown limited efficacy in an unselected population of patients. The KRAS mutations, which are identified in approximately 20% of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jieun, Cho, Yong-Hee, Shin, Wook-Jin, Lee, Sang-Kyu, Lee, JaeHeon, Kim, Taehyung, Cha, Pu-Hyeon, Yang, Jee Sun, Cho, Jaebeom, Min, Do Sik, Han, Gyoonhee, Lee, Ho-Young, Choi, Kang-Yell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345925/
https://www.ncbi.nlm.nih.gov/pubmed/30679620
http://dx.doi.org/10.1038/s41598-018-37059-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345925/
https://www.ncbi.nlm.nih.gov/pubmed/30679620
http://dx.doi.org/10.1038/s41598-018-37059-8

Ejemplares similares